Home

Channel Therapeutics Corporation Common Stock (CHRO)

1.3500
+0.00 (0.00%)
NYSE · Last Trade: Jul 4th, 3:47 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1.350
Open-
Bid1.180
Ask1.490
Day's RangeN/A - N/A
52 Week Range0.4500 - 3.800
Volume0
Market Cap8.90M
PE Ratio (TTM)-1.125
EPS (TTM)-1.2
Dividend & YieldN/A (N/A)
1 Month Average Volume146,397

Chart

News & Press Releases

Get insights into the top gainers and losers of Tuesday's pre-market session.chartmill.com
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Via Chartmill · July 1, 2025
Why Is Channel Therapeutics Stock Surging On Friday?benzinga.com
Channel Therapeutics shares rise after announcing 10-for-1 reverse stock split and upcoming rebrand.
Via Benzinga · June 27, 2025
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · May 14, 2025
EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Modelsbenzinga.com
Channel Therapeutics reports CT2000 reduced eye pain in preclinical trials, with plans to enter human testing for acute and chronic indications.
Via Benzinga · May 14, 2025
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · April 21, 2025
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · April 17, 2025
Power Metallic (OTCQB: PNPNF | TSX.V: PNPN): An Undervalued Critical Metals Stock Alongside HTZ, SMX, TGL, CHRO – Trading Under $5
Power Metallic Mines Inc. (TSX-V: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV) has reported new drill results from its Winter 2025 campaign at the Tiger Zone, returning shallow polymetallic hits and confirming early signs of Lion-style, copper-dominant mineralization in this high-priority area.
Via AB Newswire · April 17, 2025
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earningsbenzinga.com
Via Benzinga · April 17, 2025
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elatedstocktwits.com
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.
Via Stocktwits · April 17, 2025
Dow Falls Over 1%; US Initial Jobless Claims Declinebenzinga.com
Via Benzinga · April 17, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 17, 2025
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entitybenzinga.com
Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.
Via Benzinga · April 17, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 23, 2025
Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · November 26, 2024
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Via Benzinga · October 18, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 18, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · October 16, 2024
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · October 4, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 4, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 1, 2024
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · September 26, 2024
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
By Virtual Investor Conferences · Via GlobeNewswire · September 16, 2024
CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024investorplace.com
Chromocell Therapeutics just reported results for the second quarter of 2024.
Via InvestorPlace · August 20, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · May 29, 2024
CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024investorplace.com
Chromocell Therapeutics just reported results for the first quarter of 2024.
Via InvestorPlace · May 20, 2024